Institut Des Neurosciences De La Timone

Running trials

• Not yet recruiting

  Efficacy of FLUOXETINE in children with drug-resistant, complex and rare epilepsy (FLUOXEPIL)

  2024-519897-38-01· Phase 3· Source

• Recruiting

  A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3

  NCT06887348· Phase 4· Source

• Recruiting

  A First-in-human Study of S230815 in Pediatric Participants With KCNT1-related Developmental and Epileptic Encephalopathy

  NCT07227857· Phase 1/2· Source

• Recruiting

  Metronomic Chemotherapy in Wilms Tumor (MetroWilms-1906)

  NCT05384821· Phase 1/2· Source

• Recruiting

  Stereotaxic Body Irradiation of Oligometastase in Sarcoma (Stereosarc)

  NCT03548428· Phase 2· Source

• Recruiting

  A multicentre trial evaluating the combination of a MEK inhibitor and a PDL1 inhibitor in pediatric and adult patients with locally advanced and/or metastatic soft tissue sarcoma

  2024-510712-75-00· Phase 1/2· Source

• Active, not recruiting

  Adjuvant immunotherapy after salvage surgery in head and neck squamous cell carcinoma: phase 2 trial evaluating the efficacy and the toxicity of nivolumab alone, and of the combination nivolumab and ipilimumab

  2024-516810-39-00· Phase 2· Source

• Recruiting

  European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors

  NCT02813135· Phase 1/2· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers3 recruiting
• Epilepsy2 recruiting
• Kidney cancer1 recruiting
• Liver and biliary tract cancer1 recruiting
• Melanoma1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  Reperfusion with P2Y12 inhibitors in addition to mechanical thrombectomy for perfusion imaging selected acute stroke patients : a multicentric randomized controlled trial

  NCT04667078· Phase 4· Source

• Completed

  A Phase 1/2, Open-Label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Antineoplastic Activity of IPH6501 in Patients with Relapsed and/or Refractory CD20-expressing Non-Hodgkin Lymphoma

  NCT06088654· Phase 1/2· Source